Form 4: Criteo CEO Komasinski Granted 141,700 Shares

Criteo S.A. CEO Michael Komasinski was granted 141,700 ordinary shares, subject to a time-based vesting schedule.

Summary

• Michael Komasinski, CEO and Director of Criteo S.A. (CRTO), was granted 141,700 Ordinary Shares.
• The transaction date for this grant was March 13, 2026.
• The shares were acquired at a price of $0, indicating an equity grant rather than a purchase.
• Following this transaction, Michael Komasinski beneficially owns a total of 361,106 Ordinary Shares.
• The shares are subject to time-based vesting: 25% will vest on the one-year anniversary of the grant date, with the remainder vesting in equal portions quarterly over the subsequent 36 months.
• A contingency exists: if the Company's conversion into a Luxembourg company is not completed before the first anniversary of the grant date, then 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions quarterly over the subsequent two-year period.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of the CEO's long-term interests with shareholders through equity compensation. It's a routine insider transaction, not indicative of significant operational changes.

Positives

• The grant of 141,700 Ordinary Shares to the CEO aligns management's interests with those of shareholders, incentivizing long-term performance.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged and transparent approach to insider equity transactions.

Risks

• The vesting schedule is contingent on the completion of the Company's conversion into a Luxembourg company, introducing uncertainty regarding the timing and proportion of initial vesting.
• The value of the granted shares is subject to the future market performance of Criteo S.A.'s Ordinary Shares.

Future Outlook

The equity grant to the CEO, with its multi-year vesting schedule, indicates a strategic move to retain key leadership and align their long-term incentives with the company's performance. The contingency related to the Luxembourg company conversion suggests an ongoing corporate restructuring or re-domiciliation process that could impact future governance and operational frameworks.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that equity grants with multi-year vesting schedules are a standard practice in the technology and ad-tech industries for executive compensation. This approach is designed to align the interests of top management with long-term shareholder value creation and to incentivize retention. The mention of a Rule 10b5-1 plan is also a common best practice for insiders to manage their equity holdings transparently and avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• Equity grants with performance or time-based vesting are a common component of executive compensation packages across the global technology sector, comparable to practices at companies like Google, Meta, and Adobe.
• The use of a Rule 10b5-1 plan for insider transactions is a widely adopted governance standard, reflecting adherence to best practices for managing insider trading risks, similar to those observed in major U.S. and European listed companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the CEO's financial incentives with the long-term performance of the company, potentially benefiting shareholders through increased focus on value creation.
• Employees: May signal stability in leadership and a commitment to long-term strategy.

Next Steps

• Vesting of the granted shares will occur over time, contingent on the specified schedule and the completion status of the Company's conversion into a Luxembourg company.

Key Dates

Keywords

Criteo, CRTO, Michael Komasinski, Form 4, insider transaction, equity grant, CEO compensation, vesting schedule, Rule 10b5-1, corporate governance